| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 08/14/2023 | 1263.64% | Roth MKM | → $15 | Reiterates | Buy → Buy |
| 08/14/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 07/07/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 06/26/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 06/23/2023 | 1445.45% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 05/31/2023 | 1263.64% | Roth MKM | → $15 | Initiates Coverage On | → Buy |
| 04/28/2023 | 1445.45% | HC Wainwright & Co. | $20 → $17 | Maintains | Buy |
| 03/27/2023 | 1718.18% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 03/20/2023 | 1718.18% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 03/01/2023 | 309.09% | HC Wainwright & Co. | → $4.5 | Reiterates | → Buy |
| 02/27/2023 | 172.73% | Piper Sandler | $4 → $3 | Maintains | Overweight |
| 02/27/2023 | 309.09% | HC Wainwright & Co. | $7 → $4.5 | Maintains | Buy |
| 09/16/2022 | 263.64% | Piper Sandler | $3 → $4 | Maintains | Overweight |
| 08/15/2022 | 536.36% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 05/23/2022 | 172.73% | Piper Sandler | $8 → $3 | Maintains | Overweight |
| 07/09/2021 | 627.27% | Jefferies | → $8 | Initiates Coverage On | → Buy |
| 03/17/2021 | 627.27% | HC Wainwright & Co. | $5 → $8 | Maintains | Buy |
| 12/10/2019 | 354.55% | HC Wainwright & Co. | $2 → $5 | Reiterates | → Buy |
| 11/14/2019 | 81.82% | HC Wainwright & Co. | $9 → $2 | Maintains | Buy |
What is the target price for ASLAN Pharma (ASLN)?
The latest price target for ASLAN Pharma (NASDAQ: ASLN) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $17.00 expecting ASLN to rise to within 12 months (a possible 1445.45% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ASLAN Pharma (ASLN)?
The latest analyst rating for ASLAN Pharma (NASDAQ: ASLN) was provided by HC Wainwright & Co., and ASLAN Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for ASLAN Pharma (ASLN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ASLAN Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ASLAN Pharma was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating ASLAN Pharma (ASLN) correct?
While ratings are subjective and will change, the latest ASLAN Pharma (ASLN) rating was a reiterated with a price target of $0.00 to $17.00. The current price ASLAN Pharma (ASLN) is trading at is $1.10, which is within the analyst's predicted range.